DNASE1L3 and lupus nephritis: Moreover, injection of DNase I in patients with the autoimmune disease lupus nephritis, where insufficient DNase I activity is believed to be a part of the disease mechanism, did not generate any safety signals.64 Collectively, these data indicate that systemic administration of DNase I is a safe therapeutic option to remove NETs.